четверг, 23 июня 2011 г.

Psychological Interventions May Help Premenstrual Syndrome

A review article which is published in the current issue of Psychotherapy and Psychosomatics indicates that psychological interventions may help premenstrual syndrome.


A group of canadian investigators conducted a systematic review and meta-analysis to determine the efficacy of psychological interventions for premenstrual syndrome.They systematically searched and selected studies that enrolled women with premenstrual syndrome in which investigators randomly assigned them to a psychological intervention or to a control intervention. Trials were included irrespective of their outcomes and, when possible, they conducted meta-analyses.


Nine randomized trials, of which 5 tested cognitive behavioural therapy, contributed data to the meta-analyses. Low quality evidence (design and implementation weaknesses of the studies, possible reporting bias) suggests that cognitive behavioural therapy significantly reduces both anxiety (effect size [ES] = -0.58; 95% confidence interval [CI] = -1.15 to -0.01; number needed to treat [NNT] = 5), and depression (ES = -0.55; 95% CI = -1.05 to -0.05; NNT = 5), and also suggests a possible beneficial effect on behavioural changes (ES = -0.70; 95% CI = -1.29 to -0.10; NNT = 4) and interference of symptoms on daily living (ES = -0.78; 95% CI = -1.53 to -0.03; NNT = 4). Results provide much more limited support for monitoring as a form of therapy and suggest the ineffectiveness of education. Low quality evidence from randomized trials suggests that cognitive behavioural therapy may have important beneficial effects in managing symptoms associated with premenstrual syndrome.


PSYCHOTHERAPY AND PSYCHOSOMATICS

karger/pps

вторник, 21 июня 2011 г.

Sen. Coburn Should Lift Hold On Genetic Discrimination Bill, Editorial Says

Sen. Tom Coburn (R-Okla.) "should lift his hold" on a bill (HR 493), sponsored by Rep. Louise Slaughter (D-N.Y.), that would prohibit health insurers or employers from accessing the genetic information of patients or employees and considering it for hiring, firing and other business decisions, a Boston Globe editorial says (Boston Globe, 5/2). The Senate Health, Education, Labor and Pensions Committee on Jan. 31 approved a similar bill (S 358), sponsored by Sen. Olympia Snowe (R-Maine). Snowe has said she introduced the legislation, called the Genetic Information Nondiscrimination Act of 2007, because some women have said they were reluctant to be tested for genetic alterations that indicate increased risk of developing breast cancer because they feared difficulty in acquiring health insurance if they tested positive (Kaiser Daily Women's Health Policy Report, 4/27).

According to the Globe, Coburn objected to legislation that passed the Senate HELP Committee because he said it contained an exception allowing discrimination based on genetic information from embryos and fetuses. However, the House-approved measure "contains language closing that loophole" and gives Coburn "what he want[s]," the editorial says. The "importance" of the legislation "will only grow as technology evolves," the editorial says, adding that Coburn should "let the Senate get on with passing" it (Boston Globe, 5/2).

"Reprinted with permission from kaisernetwork. You can view the entire Kaiser Daily Health Policy Report, search the archives, or sign up for email delivery at kaisernetwork/dailyreports/healthpolicy. The Kaiser Daily Health Policy Report is published for kaisernetwork, a free service of The Henry J. Kaiser Family Foundation . © 2005 Advisory Board Company and Kaiser Family Foundation. All rights reserved.

McCain Campaign Criticizes Romney's Abortion-Rights Position Shift

The campaign of Sen. John McCain (R-Ariz.), who is running for the 2008 Republican presidential nomination, on Wednesday released a 2005 video in which former Massachusetts Gov. Mitt Romney (R), who also is running for the nomination, affirms his support for maintaining Massachusetts' abortion-rights laws, the Washington Post reports (Goldfarb, Washington Post, 6/14).

Since Romney first ran for U.S. Senate in 1994, he has acknowledged that his position on abortion has changed from supporting abortion rights to saying that he would prefer to have Roe v. Wade -- the 1973 Supreme Court case that effectively barred state abortion bans -- overturned. Romney in 1994 said, "I believe that abortion should be safe and legal in this country," adding, "I believe that since Roe v. Wade has been the law for 20 years, we should sustain and support it." When he ran for Massachusetts governor in 2002, Romney promised to "preserve the status quo" on abortion rights in the state and oppose any changes to state laws that restricted or increased access to abortion.

Romney in 2004 while studying human embryonic stem cell research said he experienced an awakening that led him to believe "the sanctity of life had been cheapened" by the Roe decision (Kaiser Daily Women's Health Policy Report, 4/27). Romney in the video -- taken at a May 27, 2005, press conference -- said, "I am absolutely committed to my promise to maintain the status quo with regards to laws relating to abortion and choice." He added that his "personal, philosophical views" about the issue would not have done "anything other than distract" from what he thought was a "more critical agenda" (Washington Post, 6/14).

Matt David, a spokesperson for the McCain campaign, said that Romney's "biggest challenge" in the election will be "convincing Republicans he has principled positions on important issues, especially now that it's known that he remained committed to pro-choice policies" after he shifted his position on abortion rights in 2004 (Sidoti, AP/Houston Chronicle, 6/13). Romney spokesperson Kevin Madden said the McCain campaign used a selective quote from the video and ignored Romney's other comments "where he also made a passionate case for his veto of stem cell legislation that showed a level of disregard for the sanctity of human life" (Whitesides, Reuters, 6/13).

Group Calls for IRS Investigation of Bishop's Comments About Giuliani
In related news, Americans United for Separation of Church and State on Wednesday said that Roman Catholic Bishop Thomas Tobin -- head of the Roman Catholic Diocese of Providence, R.I. -- violated tax law when he criticized Republican presidential candidate and former New York City Mayor Rudy Giuliani's support for abortion rights, the Providence Journal reports. The group is asking the Internal Revenue Service to investigate the diocese reports (Providence Journal, 6/14).














Tobin in a column for the diocese's newspaper, the Rhode Island Catholic, said Giuliani's "public proclamations on abortion are pathetic and confusing," adding, "Even worse, they're hypocritical." Tobin also said that he never would support a candidate who supports abortion rights. According to Tobin, Catholics are "required to be pro-life, to cherish and protect human life as a precious gift of God from the moment of conception until the time of natural death" (Kaiser Daily Women's Health Policy Report, 6/6).

Barry Lynn, executive director of AUSCS, in a letter to the IRS said Tobin "appears to have violated federal tax law by attacking Giuliani." The group in a statement said that "federal tax law forbids non-profits to use organizational resources to support or oppose candidates for public office." Lynn said that if Tobin "wants to join the political fray, he should do so as an individual without dragging along his tax-exempt diocese" (Providence Journal, 6/14). He added, "The bishop is not a political boss, and he shouldn't be telling his flock with church resources which candidate to oppose."

IRS spokesperson Eric Smith said the agency does not confirm an investigation's existence until it makes a ruling. Tobin spokesperson Michael Guilfoyle said the complaint does not have merit. According to the Associated Press, the IRS rarely revokes a group's tax-exempt status for one violation (Henry, Associated Press, 6/13).


The AUSCS letter to the IRS is available online.

"Reprinted with permission from kaisernetwork. You can view the entire Kaiser Daily Health Policy Report, search the archives, or sign up for email delivery at kaisernetwork/dailyreports/healthpolicy. The Kaiser Daily Health Policy Report is published for kaisernetwork, a free service of The Henry J. Kaiser Family Foundation . © 2005 Advisory Board Company and Kaiser Family Foundation. All rights reserved.

Head-To-Head Comparison Of Incontinence Treatments

As part of a national clinical trial, UT Southwestern Medical Center researchers found little difference in effectiveness between two popular treatments for one of the most common ailments among American women: stress urinary incontinence.



Stress incontinence affects up to 50 percent of women in the U.S. at some point in their lives. Women with stress incontinence experience leakage during increases in abdominal pressure typically brought on by sneezing, coughing, lifting heavy objects or other types of physical activities. UT Southwestern surgeons and colleagues at eight other sites compared the outcomes of two surgical procedures designed to alleviate symptoms of stress urinary incontinence. UT Southwestern was the only site in North Texas to participate in the trial.



The study, available online in the New England Journal of Medicine, shows that both surgical procedures - transvaginal sling (TVT) and transobturator midurethral sling (TOT) -appear to be similarly effective in women up to 12 months after the procedures were performed.



"Both procedures are done using minimally invasive techniques, but until now there haven't been any large prospective head-to-head randomized trials comparing the two popular techniques," said Dr. Gary Lemack, professor of urology and neurology and co-principal investigator at the UT Southwestern site.



The TVT sling, introduced in 1996, involves placing a thin strip of polypropylene mesh weave transvaginally and behind the urethra and pubic bone. The strip acts as a kind of scaffolding that supports the urethra, diminishing urine leakage.



The more recently developed TOT sling reduces the risk of bladder or bowel injury by passing the sling laterally into the groin through two small incisions in the upper thigh. This method works in the same way as the TVT, by supporting the urethra. Controversy exists as to which sling is more effective and which might be associated with a greater risk of complications.



"At one year, the two groups of patients were assessed both objectively and subjectively about the success of their procedures," said Dr. Lemack. "The outcomes appear very similar at one year regardless of the severity of the patient's stress incontinence symptoms."



Objective measures of success included testing whether or not there was any urine leakage with straining or coughing during an exam with a full bladder. Patients also were asked to wear a pad for 24 hours to determine if leakage occurred. Subjective self-reported criteria required patients to keep a three-day diary and record any symptoms of stress incontinence. They also reported the need for any further treatments.



"The rates of success using objective measures in patients with the transvaginal sling were around 81 percent, and 78 percent for patients who had the TOT procedure - equivalent by our preset criteria," Dr. Lemack said. "Rates of subjectively reported success were slightly higher in the transvaginal group and thus did not quite meet the criteria for equivalence."



Both procedures carry associated risks, albeit infrequently, and the key difference between procedures may be the rate of adverse events associated with each. For example, the TVT was associated with a greater likelihood of intraoperative bladder injury and postoperative voiding dysfunction, while the TOT was more likely to be associated with postoperative numbness and pain.



As a result, although the procedures are similar in effectiveness, Dr. Lemack says physicians could use the information gleaned from this study to more fully counsel patient about the risks and benefits of either operation.



Dr. Lemack said that future studies should help determine if any other parameters, such as bladder function studies, may help in predicting treatment success.



Other UT Southwestern faculty participating in the multi-center incontinence network included Dr. Philippe Zimmern, professor of urology; Dr. Joseph Schaffer, professor of obstetrics and gynecology; Dr. Marlene Corton, associate professor of obstetrics and gynecology; and Dr. Clifford Wai, associate professor of obstetrics and gynecology.



Funding for this study was provided by the National Institute of Diabetes and Digestive and Kidney Diseases and by the National Institute of Child Health and Human Development.



Source:

Katherine Morales

UT Southwestern Medical Center

Women Previously Diagnosed With Abnormal Cervical Cell Growth At Higher Risk For Recurrence And Invasive Cancer

New research from the UC Davis Center for
Healthcare Policy and Research has found that women who have been treated
for cervical intraepithelial neoplasia (abnormal cervical cell growth),
are at higher risk for a recurrence of the disease or invasive cervical
cancer.



The large, population-based study, which appears in the May 12 online
issue of the Journal of the National Cancer Institute, sheds new light on
the long-term risks of subsequent abnormal cell growth or invasive cancer,
and should help in the development of follow-up treatment guidelines for
women with a history of treatment for abnormal cells.



"We now have a much more clear idea of the risks of recurrent abnormal
cells and invasive cervical cancer over time after treatment of these
cells," said Joy Melnikow, Professor of Family and Community Medicine and
Associate Director of the UC Davis Center for Healthcare Policy and
Research, who led the study. "Recurrence risk depends on the grade of
abnormal cells that was initially treated, what treatment was used, and
the woman's age."



In the study, which used data from the British Columbia Cancer Agency
cytology database and was funded by a grant from the National Cancer
Institute, Melnikow and colleagues identified 37,142 women who were
treated for abnormal cells from Jan. 1, 1986 through Dec. 31, 2000.



They compared them with a group of 71,213 women with no previous diagnosis
of abnormal cells. Both groups were under active surveillance through
2004.



They found that risk of subsequent abnormal cells or cervical cancer was
associated with the type of treatment they received, their age, and the
initial grade of diagnosis. There are three levels of abnormal cervical
cells; grade 3 is the most severe. There is no standard treatment for
abnormal cells; at early stages, abnormal cells are monitored to determine
if they resolve without treatment.



At later stages, the type of treatment depends on several variables,
including the grade and distribution of the abnormal cells and whether the
patient has been treated previously.



According to the study, the risk of invasive cervical cancer and
recurrence of grade 2 or grade 3 abnormal cells was highest for women who
were older than 40, previously treated for grade 3, or treated with
cryotherapy, a common treatment method in which the abnormal cells are
frozen to stop their growth. Rates of recurrence at grades 2 and 3 were
lowest among women treated with cone biopsy, a method in which the
abnormal cells are removed surgically.



Melnikow said the findings could help guide physicians in making
recommendations about the intensity of follow up needed after treatment
for abnormal cells. In addition, she said the findings may help physicians
and patients in deciding which type of treatment for abnormal cells to
choose. She explained, for example, that while cryotherapy was associated
in the study with a higher risk of recurrence, it carries less risk of
other harmful effects than cone biopsy or loop electrical excision,
procedures which have been associated with pre-term delivery in women who
later become pregnant.
















This suggests that a younger woman with grade 2 abnormal cells who plans
to start a family might opt for cryotherapy, while an older woman with
grade 3 abnormal cells who is at greater risk for recurrence might opt for
loop excision or cone biopsy.



"These data may help inform that treatment discussion, because we know
more about how age and different treatments appear to influence risks,"
Melnikow said.



The study also found that the highest rates of recurrence of abnormal
cells were observed in the first six years after treatment; the majority
of those were identified in the first two years. Recurrence rates for
grade 2 or grade 3 abnormal cells during the 6-year period ranged from 2.3
percent in the lowest risk group to 35 percent in the highest risk group.
Overall incidence of cervical cancer in the abnormal cell group was 37
cervical cancers per 100,000 woman-years, compared with six cervical
cancers per 100,000 woman-years among women not previously diagnosed.



Melnikow pointed out that the study also has different implications for
health policy depending on the health system and resources. In developing
countries where cervical cancer screening and treatment are more limited
and death rates higher for cervical cancer, cryotherapy, a simpler and
less expensive treatment method for abnormal cells, is likely to be
preferred.



Melnikow said the next step is to compare different treatment and
surveillance strategies in terms of cost-effectiveness.



Source
UC Davis Health System

Women Who Give Birth At California Hospitals Serving Mostly Minority, Low-Income Patients Less Likely Than Others To Breastfeed, Report Indicates

Women who give birth at California hospitals serving mostly non-white, low-income women and children are less likely to breastfeed than women who give birth at other hospitals around the state, according to a report released from the University of California-Davis Human Lactation Center and the California WIC Association, the Riverside Press-Enterprise reports (Dean, Riverside Press-Enterprise, 9/2). Research has shown that breastfeeding can reduce the likelihood of childhood obesity and ear infections and boosts children's immune systems (Reiter, Merced Sun-Star, 9/3). Hospitals with the highest rates of women who exclusively breastfed had trained staff, made lactation specialists available and supported exclusive breastfeeding, unless there was a medical reason not to, the Modesto Bee reports.

The report found, for example, that about 59% of white women in Stanislaus County who gave birth at hospitals reported breastfeeding their newborns exclusively, while 33% of Hispanic women and 32% of black women said they exclusively breastfed. The report's findings raise concerns that more targeted efforts are needed to address cultural gaps, according to the Bee (Carlson, Modesto Bee, 9/3).

Eighty-seven percent of women statewide began breastfeeding while at the hospital, the report found (Riverside Press-Enterprise, 9/2). However, an average of 42.7% of women continued to exclusively breastfeed their infants after leaving the hospital, according to the report (Halstead, Marin Independent Journal, 9/2). The California Department of Public Health has guidelines to help hospitals promote breastfeeding and emphasizes exclusive breastfeeding in the hospital, which can influence whether the infant will be breastfed at home (Modesto Bee, 9/3). Lisa Keckler, head of a breastfeeding quality improvement task force at Doctors Medical Center of Modesto, said that the hospital's lower breastfeeding rates could be explained by some premature infants having to spend time in intensive care. In addition, some women might have to return to work soon after giving birth and supplement breastfeeding with formula, she added.

The report also found that California hospitals with the World Health Organization's "baby-friendly" designation reported higher rates of women who breastfeed exclusively after leaving the hospital (Modesto Bee, 9/3). The program involves 10 steps to help improve breastfeeding rates and lower infant mortality rates and can include classes, lactation counseling and other services to assist women after giving birth (Riverside Press-Enterprise, 9/2). At the 19 baby-friendly hospitals in California, 71% of white women, 66% of Hispanic women and 62% of black women breastfed (Modesto Bee, 9/3).














Karen Farley, program manager of California WIC Association, said, "Our report shows that virtually all of the hospitals with the lowest exclusive breastfeeding rates reported here serve low-income and minority women -- the very population most affected by poor health outcomes such as diabetes and obesity" (Riverside Press-Enterprise, 9/2). She added, "Breastfeeding should not depend on where you are born. We know that when babies are exclusively breastfed in the hospital, they are more likely to be breastfed exclusively at home. We know these babies have healthier outcomes" (Modesto Bee, 9/3).


The report is available online.


Reprinted with kind permission from kaisernetwork. You can view the entire Kaiser Daily Health Policy Report, search the archives, or sign up for email delivery at kaisernetwork/dailyreports/healthpolicy. The Kaiser Daily Health Policy Report is published for kaisernetwork, a free service of The Henry J. Kaiser Family Foundation.

© 2008 Advisory Board Company and Kaiser Family Foundation. All rights reserved.

Revision Of WHO Guidelines For Treating Some HIV-Infected Women Influenced By OCTANE Study

Findings from a study, winNew England Journal of Medicine, helped influence the World Health Organization (WHO) to change its guidelines this year for the treatment of HIV-infected women who receive a single dose of the antiretroviral drug nevirapine to prevent HIV transmission to their babies. The study demonstrated that the single dose of nevirapine used to prevent mother-to-child transmission of HIV can hamper the drug's effectiveness if it is also used later as part of a regimen to treat these same individuals.



The Phase III study, called Optimal Combination Therapy after Nevirapine Exposure (OCTANE), enrolled 745 women at 10 sites in seven African countries to address the critical question around nevirapine resistance. The drug nevirapine is inexpensive and accessible, and is widely used in resource-constrained settings for both treating HIV and preventing mother-to-child transmission (PMTCT).



The Adult AIDS Clinical Trials Group conducted the study with funding from the National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. National Institutes of Health. The U.S. Military HIV Research Program's (MHRP) network site in Kericho, Kenya, the Kenya Medical Research Institute/Walter Reed Project, and another partner site in Eldoret, Kenya, participated in the study and enrolled 74 participants.



"This is very exciting news indeed!" said Dr. Fred Sawe, MHRP partner and the local principal investigator for the OCTANE study in Kericho. "We now have a definite answer to a problem that has continued to haunt us for the last 10 years. Given the infrastructure we have so far built in PMTCT programs, we can now minimize use of single dose only nevirapine-based interventions, increase access to more efficacious regimens, and provide better care to women who have been exposed to single-dose nevirapine without slowing down the progress of eliminating pediatric AIDS: a win-win situation of great public health importance."



An interim review of the study in 2008 found that exposing HIV-infected women to a single dose of nevirapine for PMTCT may lead these women to develop nevirapine-resistant HIV. The development of drug resistance compromises the effectiveness of HIV treatment regimens that include nevirapine. Based on this information, the study leadership advised women who were previously exposed to nevirapine and were taking nevirapine as part of the study protocol to consult with their clinicians about how to proceed with HIV treatment.



One of the additional findings in the study was that the negative effect of previous exposure to nevirapine appears to decrease with time. Researchers also found that the negative effect appears to decrease when more time elapses between taking single-dose nevirapine and starting treatment. The study also found that for those women without prior exposure to nevirapine, the drug has similar efficacy to another regimen, which included ritonavir-boosted lopinavir.



The 2010 WHO guidelines now advise that HIV-infected women who take single-dose nevirapine for PMTCT should not be treated for their own infection with a drug regimen that includes nevirapine as well as other drugs in the same class (known as non-nucleoside reverse transcriptase inhibitors, or NNRTIs), if treatment begins fewer than 12 months later and if the women were not given other antiretroviral drugs to prevent the development of nevirapine-resistant HIV.



Articles:



S Lockman et al. Antiretroviral therapies in women after single-dose nevirapine exposure. New England Journal of Medicine DOI: 10.1056/NEJMoa09-06626 (2010).



WHO. Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach - 2010 revision (2010).



Source:

Lisa Reilly

Henry M. Jackson Foundation for the Advancement of Military Medicine